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white crystalline powder with a molecular 
composition of C9H11O2N + CH3SO3H and 
molecular weight 261.31. MS-222 possesses 
moderately high stability (145 oC MP) and is 
clear, colorless, and highly soluble (to 11%) in 
aqueous solutions [1]. Solutions of pure MS-222 
become acidic due to the formation of 
methane sulfonic acid. Therefore, MS-222 
should be buffered to saturation with 
sodium bicarbonate before use as an injectable, 
to avoid metabolic imbalances in the 
anesthetized animals [2, 3].  
During procedures in our laboratory that 
involved weekly bleeding of anesthetized tilapia 
(Oreochromis niloticus), a trend of reduced time 
to anesthesia in successive weeks was suspected. 
A naïve group of tilapia was therefore 
established and anesthetized once per week for 
six consecutive weeks, which verified that time 
to anesthesia was significantly reduced upon 
repeat MS-222 exposures. This result suggested 
induction of liver enzymes with the repeated 
exposures, which more rapidly produced an 
unrecognized active metabolite of MS-222 that 
had higher anesthetic potency than the parent 
compound. In the present report, we speculate as 
to the identity of a putative more active MS-222 
metabolite, and show data for testing of its 
anesthetic potential in tilapia.  
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ABSTRACT 
A group of 8 tilapia (Oreochromis niloticus) 
were anesthetized once per week for six 
consecutive weeks, using tricaine 
methanesulfonate (MS-222) in the water. Time for 
the fish to reach anesthesia decreased 
significantly over the first four weeks, and then 
plateaued at about 27% below the first anesthetic 
exposure. These results suggest induction of the liver 
enzymes that convert MS-222 into 
metabolites, one or more of which have higher 
anesthetic activity than the parent compound. 
Major metabolites of MS-222 have been 
identified as part of regulatory studies evaluating 
residue persistence in food fishes. One of these 
metabolites, N-acetyl-3-aminobenzoic acid ethyl 
ester, which is acetylated MS-222, was selected for 
testing of anesthetic activity in tilapia. This report 
shows results of the testing, and speculates as to the 
potential utility of the acetylated metabolite of 
MS-222 as an alternate anesthetic agent in fish.  
Key Words: tilapia; fish; anesthesia; 
MS-222; tricaine  
INTRODUCTION 
Tricaine methanesulfonate (MS-222; 3-
aminobenzoic acid) is a widely used anesthetic/
tranquilizing agent for fish, reptiles, and 
amphibians, and currently the only anesthetic 
licensed by the United States Food and Drug 
Administration (FDA) for use in food fish. It is 




Eight tilapia (39 ± 2.7 g) were removed 
from a holding tank and placed into an 80-L tank 
with filtered, aerated, and dechlorinated water. 
Temperature and lighting conditions were 26 oC 
and 12/12 hr light/dark cycle. Fish were fed a 
commercial fish diet of floating pellets (Zeigler 
Bros., Inc., Gardners, PA) at approximately 2% 
body weight daily. Ammonia and nitrite levels 
were monitored weekly, and tanks were cleaned 
as needed. A two-week acclimation period was 
allowed before initiating weekly MS-222 
anesthesia. These fish had not previously been 
anesthetized with MS-222.  
MS-222 (Sigma Chemical Co., St. 
Louis, MO) was prepared by dissolving 1.2 g in 
6.0 L of dechlorinated water (thus 200 mg/L), in 
a 40-L bucket. Fish were anesthetized by 
simultaneous immersion of all eight fish in the 
MS-222 solution, with time to anesthesia 
recorded as the time when vertical equilibrium 
was lost and the fish rotated approximately 90 
degrees in the water (Stage III anesthesia). Time 
to anesthesia in the eight fish was recorded in 
this manner for six consecutive weeks. Unless 
otherwise indicated, “anesthesia” in this report 
refers to Stage III anesthesia with the loss of 
vertical equilibrium.  
Major reported metabolites of MS-222 
in fish include 3-aminobenzoic acid, N-acetyl-3-
aminobenzoic acid, and N-acetyl-3-
aminobenzoic acid ethyl ester [4] (Figure 1). 
The N-acetyl-3-aminobenzoic acid ethyl ester 
metabolite, or acetylated MS-222 (MS-222A) 
was selected as the likely more active metabolite 
of MS-222, and synthesized for testing. 
Synthesis of MS-222A was as follows. Ethyl 3-
aminobenzoate mesylate (MS-222) (5.0 g, 19 
mmol) was dissolved in 200 mL water, and 2 mL 
Ac2O was added with stirring, followed 
immediately by 1.65 g NaOAc (19 mmol). The 
clear solution became milky, and it was left 
stirring for 30 minutes. The pH was then 
adjusted to ~2 with a few drops of 12 M HCl, 
and the solution was put at 4 ºC for the product 
to complete precipitation. The precipitate was 
filtered, washed with water, and left to dry, 
giving 3.66 g (93.7%) of white powder. 1H-
NMR showed that this was the expected acetyl 
product. 
MS 222 or MS-222A, 500 or 1000 mg 
each (experiments 1 and 2, respectively), were 
dissolved in 2.5 ml dimethyl sulfoxide (DMSO) 
and added separately to buckets containing 5 L 
filtered, aerated, and dechlorinated water. The 
concentration of MS-222 or MS-222A in 
respective buckets was therefore 100 mg/L 
(experiment 1) or 200 mg/L (experiment 2). An 
additional bucket was prepared that contained 
fresh water plus 2.5 ml DMSO (vehicle control). 
Tilapia that had not been previously anesthetized 
were sequentially (individually) placed into the 
test buckets, N=5, and the time to anesthesia was 
recorded.  
Intracoelomic injection of buffered MS-
222 is used for anesthesia or euthanasia in 
reptiles and amphibians, in both research and 
clinical settings [5]. As the 2nd comparison of 
anesthetic potential, tilapia (N=4) were 
anesthetized by intracoelomic injection, 600 
mg/kg, with either buffered MS-222 or MS-
222A.  MS-222A lacks the sulfonate group that 
leads to sulfonic acid production in an aqueous 
environment, has a pH of 7.5 of when dissolved 
in water, and therefore was not buffered before 
injection.  
Immediately following intracoelomic 
anesthetic injections, tilapia were placed into five 
gal buckets containing about two gal fresh water. 
The time required for these fish to enter Stage II, 
plane 2 anesthesia, characterized by narcosis 
involving muscle relaxation and slowed 
opercular and mouth movement [2], was 
recorded. Not all fish progressed into Stage III 
anesthesia, however, time was also recorded for 
the fish that reached this level. Stage II, plane 1, 
light narcosis was observed in a few of the fish, 
characterized by a very short excitement phase 
involving rapid swimming and increased 
opercular and mouth movement, and not 
recorded as a timed observation.  
Upon reaching Stage III anesthesia, all 
fish in this report were immediately returned to 
fresh water tanks containing no anesthetic, for 
recovery. Fish that did not progress beyond 
Stage II anesthesia were in a similar manner 
returned to fresh water tanks containing no 
anesthetic, for recovery. All procedures in this 
report were reviewed and approved by the 
University of Georgia Institutional Animal Care 
and Use Committee (IACUC), before initiation 
of the studies.  
RESULTS 
Time to anesthesia decreased 
significantly with repeated exposures of tilapia to 
200 mg/L MS-222 in the water (Figure 2). Mean 
time to anesthesia was 160 seconds on the first 
exposure of tilapia to MS-222, and decreased by 
27% to 117 seconds at week 4. Mean time to 
anesthesia at weeks 4, 5 and 6 plateaued at 117, 
114 and 118 seconds, respectively, suggesting 
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maximal metabolic enzyme induction had been 
reached.  
 Fish individually (sequentially) 
exposed to 100 mg/L MS-222 in the water 
tended to require more time to reach anesthesia 
with each subsequent fish (Table 1), suggesting 
partial depletion of MS-222 by earlier fish. 
Dissolving MS-222 in DMSO before addition to 
water, did not affect time to anesthesia. Fish in 
fresh water containing the DMSO vehicle only, 
showed no signs of anesthesia. None of the fish 
exposed to 100 mg/L MS-222A in the water 
reached Stage III anesthesia.  
Fish individually exposed to 200 mg/L 
MS-222 in the water also tended to require more 
time to reach anesthesia with each subsequent 
fish tested (Table 2). None of the fish exposed to 
200 mg/L MS-222A reached Stage III 
anesthesia. Both the 100 and 200 mg/L MS-
222A fish reached Stage I anesthesia rapidly, 
including melanomacrophages induction not 
seen in MS-222 fish, however, this endpoint, 
with the lack of further anesthesia progression, 
was not anticipated before the exposure and 
therefore not timed.  
Fish injected with 600 mg/kg MS-222, 
N=4, reached Stage II, plane 2 anesthesia with 
mean time of 1 min 1 sec (Table 3). Three of 
these 4 fish did not progress to Stage 3 
anesthesia. Fish injected with 600 mg/kg MS-
222A, N=4, reached Stage II, plane 2 anesthesia, 
with a mean time 0 min 46 sec. Time to Stage II 
anesthesia was therefore numerically but not 
significantly reduced with MS-222A injection. 
All four MS-222A fish progressed to Stage III 
anesthesia, and two of the four continued into 
deepening anesthesia, and were classified as 
Stage IV (anesthetic overdose and death). One of 
the two fish classified as Stage IV, however, 
recovered after about 20 minutes, and therefore 
was reclassified to very deep Stage III.   
DISCUSSION 
The observation of reduced time to 
anesthesia in fish, upon repeated exposures to 
MS-222, indicated the formation of an 
unrecognized metabolite of MS-222 that had 
greater anesthetic activity than the parent 
compound. The three major metabolites of MS-
222 are 3-aminobenzoic acid, N-acetyl-3-
aminobenzoic acid, and N-acetyl-3-
aminobenzoic acid ethyl ester [4, 6].  3-
aminobenzoic acid is a molecule used for the 
synthesis of azo dyes, is found in yeasts, and is 
essential for the growth of many microorganisms 
[7, 8]. Anesthetic activity of 3-aminobenzoic 
acid is not suggested by its presence in yeast and 
use in cell culture media, is not indicated on 
Material Safety Data Sheets (MSDS) for this 
chemical 
(http://www.sciencelab.com/msds.php?msdsId=9
922875), and has not otherwise been reported in 
the literature.  N-acetyl-3-aminobenzoic acid is 
an active ingredient in sun-blocking creams, has 
no reported numbing effects on skin or other 
anesthetic activity [9], and anesthetic activity is 




MS-222 is a sulfonated analog of 
benzocaine, and was discovered accidentally 
during attempts to derive a synthetic substitute 
for cocaine [10, 11]. Benzocaine is structurally 
very similar to MS-222, having an NH2 (amino) 
group in the para position as compared to an 
NH3+ group in the meta position of water-
dissolved MS-222. The acetylated or N-
acetylbenzocaine metabolite of benzocaine is 
rapidly formed in vivo by acetyltransferase 
enzyme activity, has greater anesthetic activity 
than benzocaine, and is commercially available 
as a faster-acting drug [12]. N-acetyl-3-
aminobenzoic acid ethyl ester (MS-222A) differs 
from N-acetylbenzocaine by the presence of the 
N-acetyl group at the meta rather than the para
position. Given the reported enhancement of
anesthetic activity of benzocaine by acetylation,
and given lack of reported or suspected
anesthetic activity of the other major MS-222
metabolites, MS-222A was selected as the likely
major metabolite to evaluate for anesthetic
activity in fish.
Fish placed into water containing 100 
mg/L MS-222A proceeded rapidly to Stage I 
anesthesia, as characterized by reduced motion 
and melanomacrophage induction. These fish, 
however, did not progress beyond Stage I. The 
concentration of MS-222A was therefore 
increased to 200 mg/L, with the same result of 
fish rapidly reaching Stage I anesthesia but 
progressing no farther. A DMSO vehicle effect 
limiting the availability of MS-222A was not 
viewed as likely, however, a second vehicle, 200 
l ethanol, was tested in N=3 fish to answer this 
concern. The mean time to Stage III anesthesia 
for 100 mg/L MS-222 was 6 min 15 sec, and for 
100 mg/L MS-222A was 10 min 13 sec for two 
fish that achieved Stage III, while one fish did 
not progress past Stage I (full data not shown). 
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The MS-222A fish again rapidly reached Stage I 
anesthesia using the ethanol vehicle.  
The rapid progression of MS-222A fish 
to Stage I anesthesia, followed by no or lengthier 
progression to deeper anesthesia, suggested 
possible lower availability of the more lipophilic, 
acetylated metabolite in water. Fish were 
therefore injected with MS-222 or MS-222A, 
following published guidelines for intracoelomic 
anesthesia or euthanasia of poikilothermic 
species [5, 13]. The mean time to Stage II, plane 
2 anesthesia was numerically but not statistically 
more rapid in fish injected with MS-222A. One 
of four fish injected with MS-222 reached Stage 
III anesthesia following injection, while all four 
fish injected with MS-222A reached Stage III. 
Two of the MS-222A fish were then rated as 
continuing to Stage IV (overdose death), 
however, one of these two fish recovered after 20 
minutes. When injected into a group of test fish, 
MS-222A therefore exhibited stronger anesthetic 
activity than MS-222.  
Summary and Conclusions: When injected, 
MS-222A caused deeper anesthesia than did MS-
222. When dissolved in water, MS-222A caused
fish to rapidly reach Stage I anesthesia, but these
fish did not progress to deeper anesthesia.
Halting of anesthetic progression at Stage I may
suggest very rapid further metabolism of MS-
222A, by the same enzymes that metabolize
parent MS-222, but without competition from
additional MS-222 in the MS-222A treated fish.
Experiments in which fish are pre-treated with
mixed-function oxidase (MFO) inhibitors and
then exposed to either MS-222 or MS-222A in
the water are a logical next step. If MS-222 is
metabolized to a more active acetylated form,
MFO inhibition should lengthen the time to
anesthesia. Further, if MS-222A is a more active
anesthetic than MS-222, but is metabolized too
rapidly for fish to progress beyond Stage I
anesthesia, MFO inhibition should cause rapid
progression to deeper stages of anesthesia.
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Figure Legends 
Figure 1. Major metabolites of tricaine 
methanesulfonate (MS-222) 
Figure 2. Time to anesthesia on repeat exposure 
of tilapia to MS-222 
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Table 1. Time to anesthesia in tilapia exposed to 100 mg/L MS-222 or MS-222A, using a DMSO vehicle. 
MS-222 MS-222 + DMSO MS-222A + DMSO DMSO 
5:30 6:50 NA NA 
7:09 6:05 NA NA 
5:58 8:40 NA NA 
10:05 8:57 NA NA 
12:13 11:26 NA NA 
Mean 8:11 Mean 8:32 
NA: Stage III anesthesia not attained 








NA: Stage III anesthesia not attained 
Table 3. Time to Stage II or Stage III anesthesia in tilapia injected with 600 mg/kg MS-222 or MS-222A, 









0:48 NA 1:05 2:09 
1:14 NA 1:11 1:30 
0:20 1:40 0:30 3:46 
1:43 NA 0:19 0:39 
Mean 1:01 - Mean 0:46 Mean 2:01 
NA: Stage III anesthesia not attained 
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Figure 2. Time to anesthesia on repeat exposure of 
tilapia to MS-222. 
Figure 1. Major metabolites of tricaine 
methanesulfonate (MS-222). 
